文献速递真菌感染医院感染防控细菌感染、耐药与抗菌药物

耳念珠菌(原 Candida auris):耐药、持久且无处不在

Candidozyma auris (formerly Candida auris): resistant, long lasting, and everywhere.
PubMed 文献 · Clin Microbiol Infect · 2026-01-02

本文为叙述性综述,汇总2009至2025年文献,阐述耳念珠菌的分类学、流行病学、临床影响、耐药性、传播及感染防控。该菌已呈全球地方性流行,念珠菌血症平均死亡率约30%,唑类耐药广泛,防控面临筛查与实验室鉴定等挑战。

要点

  • 耳念珠菌已呈多洲地方性流行,念珠菌血症平均死亡率约30%。
  • 唑类耐药在多个分支中广泛存在,两性霉素B和棘白菌素耐药报告增多。
  • 暴发由环境持久性、长期皮肤定植和医疗相关传播驱动,需强化感染防控。

核心结论

  • 耳念珠菌全球持续扩张,正从暴发 emergence 转向多地地方性流行,需协调区域与国际应对。

研究设计与样本

  • 叙述性综述,检索2009至2025年PubMed/MEDLINE、Embase、Scopus、Web of Science及WHO、CDC等机构网站文献。

主要发现

  • 念珠菌血症平均死亡率约30%,因地区和患者人群而异。
  • 唑类耐药在多个分支中广泛存在,两性霉素B和棘白菌素耐药在高流行区报告增多。
  • 暴发由环境持久性、长期皮肤定植和医疗相关传播维持,重症监护暴露、抗菌药物压力和COVID-19期间系统压力可放大传播。

临床怎么用

  • 需持续投入实验室能力、采用标准化命名、主动监测、基因组监测及针对该菌独特生物学的严格感染防控措施。

局限性

  • 筛查、去定植、实验室鉴定和长期暴发控制方面仍存在重大挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive fungal diseases represent a significant global health concern, with Candidozyma auris (formerly Candida auris) emerging as a major healthcare-associated pathogen. Its multidrug resistance, environmental persistence, prolonged skin colonization, and efficient nosocomial transmission have driven sustained outbreaks and endemicity worldwide, and recent taxonomic changes have further complicated surveillance and diagnostics. OBJECTIVES: This narrative review summarizes current evidence on the taxonomy, epidemiology, clinical impact, antifungal resistance, transmission, and infection prevention and control (IPC) of C. auris, highlighting outbreak drivers, regional endemicity, and key gaps relevant to surveillance and policy. SOURCES: We conducted a structured narrative review of peer-reviewed and grey literature published between 2009 and 2025, drawing from PubMed/MEDLINE, Embase, Scopus, Web of Science, and major public health websites, such as the WHO, the CDC, the European Centre for Disease Prevention and Control, the UK Health Security Agency, and national surveillance portals. CONTENT: C. auris has rapidly evolved into an endemic healthcare threat across multiple continents, with substantial regional variation in incidence, outbreak dynamics, antifungal resistance, and control capacity. Candidemia mortality averages ∼30% but differs by region and patient population. Azole resistance is widespread in several clades, whereas resistance to amphotericin B and echinocandins is increasingly reported, particularly in high-endemic settings. Outbreaks are sustained by environmental persistence, prolonged skin colonization, and healthcare-associated transmission, amplified by intensive care exposure, antimicrobial pressure, and system strain during the COVID-19 pandemic. Despite broadly aligned IPC guidance, major challenges persist in screening, decolonization, laboratory identification, and long-term outbreak control. IMPLICATIONS: The continued global expansion of C. auris has major clinical, economic, and public health implications. Effective control requires sustained investment in laboratory capacity, standardized nomenclature adoption, active surveillance, genomic monitoring, and rigorous IPC measures tailored to the pathogen's unique biology. Without coordinated regional and international responses, C. auris is likely to continue shifting from epidemic emergence to entrenched endemicity in diverse healthcare systems worldwide.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Salmanton-García J, Nóbrega de Almeida J, Colombo AL, et al. Candidozyma auris (formerly Candida auris): resistant, long lasting, and everywhere. Clin Microbiol Infect. 2026. PMID: 41485706. doi:10.1016/j.cmi.2025.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。